Generic Name and Formulations:
Treprostinil 1mg/mL, 2.5mg/mL, 5mg/mL, 10mg/mL; soln for SC or IV continuous infusion.
United Therapeutics Corp.
Indications for REMODULIN:
Pulmonary arterial hypertension (PAH) in patients with NYHA Class II–IV symptoms, to diminish symptoms associated with exercise. PAH patients requiring transition from Flolan (epoprostenol), to reduce the rate of clinical deterioration.
>16yrs: Give preferably by SC infusion; if not tolerated, may give by IV infusion (dilution required). Treatment-naïve: initially 1.25ng/kg/min (or 0.625ng/kg/min, if not tolerated); may increase dose based on response by increments of 1.25ng/kg/min per week for 1st 4 weeks of treatment, then 2.5ng/kg/min per week. Infusion rate: see full labeling. Doses >40ng/kg/min: limited experience. Mild-to-moderate hepatic insufficiency: initially 0.625ng/kg/min; increase cautiously. Severe hepatic insufficiency: not studied. Transition from Flolan (epoprostenol): increase treprostinil dose gradually as the epoprostenol dose is decreased, based on response; see full labeling.
≤16yrs: not recommended.
Should be administered by experienced clinicians in PAH diagnosis and treatment. IV route: risk of blood stream infections and sepsis; may be fatal. Low systemic arterial pressure: risk of symptomatic hypotension. Avoid abrupt withdrawal or sudden large dose reduction. Hepatic or renal insufficiency; titrate gradually. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
May be potentiated by CYP2C8 inhibitor (eg, gemfibrozil) and antagonized by CYP2C8 inducer (eg, rifampin); may need to adjust dose.
Infusion reactions/site pain, headache, diarrhea, nausea, jaw pain, vasodilatation, edema, hypotension; bleeding.
Multidose vials (20mL)—1
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force